Durvalumab, a therapeutic anti-PD-L1 antibody [31, 32], did not affect migration of the BEAS-2B cells, suggesting that the anti-tumor activity of antibody binding PD-L1 does not involve disruption of PD-L1's control of migration (Fig. 3B, J, Additional file 1: Fig. S3B). This evidence concerns the gene CD274 and neoplasm.